Pipeline

Overview of the REACT® Clinical Program

Lead Platform Programs*

  • Preclin
  • IND
  • Ph 1
  • Ph 2
  • Ph 3
  • Approv
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/DKD

Diabetes Type II – Prevent/Delay CKD 3/4 

(20-50 ml/min/1.73m2, N=81)
Fully Enrolled

Diabetes Type II – Prevent/Delay CKD 3/4

(20-50 ml/min/1.73m2, N=1,200)
Enrolling in US

Diabetes Type II –
Delay CKD 4/5 

(14-20 ml/min/1.73m2, N=10)
Trial completed

Diabetes Repeat Dose Prevent/Delay CKD 3/4 

(20-50 ml/min/1.73m2, N=50)
enrollment completed
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3
  • Approval

REACT®/CAKUT

Congenital Anomalies – Prevent/Delay N=15

trial completed

Footnotes:

† injecting both kidneys w/ redose trigger

‡ Increased from 30 as indicated in Proxy Amendment No. 1, page 289